Product Description
TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29748212/)
Mechanisms of Action: dUTPase Inhibitor,DPD Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-001806-40 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2018-10-25 |
|
| TAS-114-201 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-09-30 |
|
| TPU-TAS-114-101 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2017-07-07 |
|
| Taiho10050020 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2017-02-01 |